Top-down approach to biological therapy of Crohn's disease

被引:13
作者
Hirschmann, Simon [1 ]
Neurath, Markus F. [1 ]
机构
[1] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Med, Med Clin 1, Erlangen, Germany
关键词
Crohn ' s disease; IBD; mucosal healing; colitis; prognosis; individualized therapy; INFLAMMATORY-BOWEL-DISEASE; EARLY COMBINED IMMUNOSUPPRESSION; EVIDENCE-BASED CONSENSUS; ANTI-TNF; OPPORTUNISTIC INFECTIONS; STEP-UP; SUBCUTANEOUS USTEKINUMAB; CONVENTIONAL MANAGEMENT; ULCERATIVE-COLITIS; CLINICAL-COURSE;
D O I
10.1080/14712598.2017.1287170
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction: Crohn's disease (CD) is a chronic, immune-mediated condition with a potentially disabling and destructive course. Despite growing data on when to use a therapeutic top-down' strategy, clinical management of this complex disorder is still challenging. Currently, the discussion of top-down' strategy in CD mostly includes biological therapy alone or in combination.Areas covered: This article is based on a review of existing literature regarding the use of biological therapy in a top-down' approach for the treatment of Crohn's disease. The authors reviewed all the major databases including MEDLINE as well as DDW and ECCO abstracts, respectively.Expert opinion: A top-down' therapeutic approach in Crohn's disease is strongly supported by existing data in patients with several risk factors for a severe course of disease. Moreover, there is an increasing amount of published data recommending a more individualised therapeutic strategy to identify candidates for top-down' treatment, based on enhanced diagnostics using biomarkers. Emerging therapeutic approaches besides existing therapy concepts using biologicals may possibly redefine the top-down' therapeutic strategy for Crohn's disease in the future.
引用
收藏
页码:285 / 293
页数:9
相关论文
共 67 条
  • [1] An update on medical management on Crohn's disease
    Affronti, Andrea
    Orlando, Ambrogio
    Cottone, Mario
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (01) : 63 - 78
  • [2] The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies
    Allez, M.
    Vermeire, S.
    Mozziconacci, N.
    Michetti, P.
    Laharie, D.
    Louis, E.
    Bigard, M. -A.
    Hebuterne, X.
    Treton, X.
    Kohn, A.
    Marteau, P.
    Cortot, A.
    Nichita, C.
    van Assche, G.
    Rutgeerts, P.
    Lemann, M.
    Colombel, J. -F.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 31 (01) : 92 - 101
  • [3] European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
    Annese, Vito
    Beaugerie, Laurent
    Egan, Laurence
    Biancone, Livia
    Bolling, Claus
    Brandts, Christian
    Dierickx, Daan
    Dummer, Reinhard
    Fiorino, Gionata
    Gornet, Jean Marc
    Higgins, Peter
    Katsanos, Konstantinos H.
    Nissen, Loes
    Pellino, Gianluca
    Rogler, Gerhard
    Scaldaferri, Franco
    Szymanska, Edyta
    Eliakim, Rami
    [J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 (11) : 945 - 965
  • [4] Treatment algorithms in Crohn's - Up, down or something else?
    Antunes, Ophelie
    Filippi, Jerome
    Hebuterne, Xavier
    Peyrin-Biroulet, Laurent
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2014, 28 (03) : 473 - 483
  • [5] Early versus late surgery for ileo-caecal Crohn's disease
    Aratari, A.
    Papi, C.
    Leandro, G.
    Viscido, A.
    Capurso, L.
    Caprilli, R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (10) : 1303 - 1312
  • [6] In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease
    Atreya, Raja
    Neumann, Helmut
    Neufert, Clemens
    Waldner, Maximilian J.
    Billmeier, Ulrike
    Zopf, Yurdaguel
    Willma, Marcus
    App, Christine
    Muenster, Tino
    Kessler, Hermann
    Maas, Stefanie
    Gebhardt, Bernd
    Heimke-Brinck, Ralph
    Reuter, Eva
    Doerje, Frank
    Rau, Tilman T.
    Uter, Wolfgang
    Wang, Thomas D.
    Kiesslich, Ralf
    Vieth, Michael
    Hannappel, Ewald
    Neurath, Markus F.
    [J]. NATURE MEDICINE, 2014, 20 (03) : 313 - 318
  • [7] Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
    Baert, Filip
    Moortgat, Liesbeth
    Van Assche, Gert
    Caenepeel, Philip
    Vergauwe, Philippe
    De Vos, Martine
    Stokkers, Pieter
    Hommes, Daniel
    Rutgeerts, Paul
    Vermeire, Severine
    D'Haens, Geert
    [J]. GASTROENTEROLOGY, 2010, 138 (02) : 463 - 468
  • [8] Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer
    Beaugerie, Laurent
    Carrat, Fabrice
    Colombel, Jean-Frederic
    Bouvier, Anne-Marie
    Sokol, Harry
    Babouri, Abdenour
    Carbonnel, Franck
    Laharie, David
    Faucheron, Jean-Luc
    Simon, Tabassome
    de Gramont, Aimery
    Peyrin-Biroulet, Laurent
    [J]. GUT, 2014, 63 (09) : 1416 - 1423
  • [9] Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis
    Bonovas, Stefanos
    Fiorino, Gionata
    Allocca, Mariangela
    Lytras, Theodore
    Nikolopoulos, Georgios K.
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (10) : 1385 - +
  • [10] Chen QQ, 2014, EXCLI J, V13, P111